[go: up one dir, main page]

FI932561A0 - Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning - Google Patents

Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning

Info

Publication number
FI932561A0
FI932561A0 FI932561A FI932561A FI932561A0 FI 932561 A0 FI932561 A0 FI 932561A0 FI 932561 A FI932561 A FI 932561A FI 932561 A FI932561 A FI 932561A FI 932561 A0 FI932561 A0 FI 932561A0
Authority
FI
Finland
Prior art keywords
protein
pharyngeal
intact epithelium
variants
epithelium
Prior art date
Application number
FI932561A
Other languages
English (en)
Other versions
FI932561A7 (fi
FI932561L (fi
Inventor
Uffe Loevborg
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI932561(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of FI932561A0 publication Critical patent/FI932561A0/fi
Publication of FI932561A7 publication Critical patent/FI932561A7/fi
Publication of FI932561L publication Critical patent/FI932561L/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38627—Preparations containing enzymes, e.g. protease or amylase containing lipase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38645—Preparations containing enzymes, e.g. protease or amylase containing cellulase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38654—Preparations containing enzymes, e.g. protease or amylase containing oxidase or reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
FI932561A 1990-12-05 1991-12-05 Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning FI932561L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90610072 1990-12-05
PCT/DK1991/000382 WO1992010755A1 (en) 1990-12-05 1991-12-05 Proteins with changed epitopes and methods for the production thereof

Publications (3)

Publication Number Publication Date
FI932561A0 true FI932561A0 (fi) 1993-06-04
FI932561A7 FI932561A7 (fi) 1993-06-04
FI932561L FI932561L (fi) 1993-06-04

Family

ID=8205875

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932561A FI932561L (fi) 1990-12-05 1991-12-05 Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning

Country Status (11)

Country Link
EP (1) EP0561907B1 (fi)
JP (3) JP3355186B2 (fi)
KR (1) KR100237968B1 (fi)
AT (1) ATE170630T1 (fi)
AU (1) AU9052891A (fi)
BR (1) BR9107206A (fi)
CA (2) CA2095852C (fi)
DE (1) DE69130113T2 (fi)
DK (1) DK0561907T3 (fi)
FI (1) FI932561L (fi)
WO (1) WO1992010755A1 (fi)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL178045B1 (pl) * 1992-07-17 2000-02-29 Genencor Int Mutant proteazy do stosowania w detergentach, sekwencja DNA kodująca mutanta proteazy, sposób otrzymywania mutanta proteazy oraz kompozycja detergentowa
EP0786085A4 (en) * 1994-10-14 1999-02-03 Chiron Mimotopes Pty Ltd EFFICIENT METHOD OF DISCOVERING MIMOTOPES AND APPARATUS THEREOF
EP1017794A1 (en) * 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
CA2324422A1 (en) * 1998-03-26 1999-09-30 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
AU2742499A (en) * 1998-03-26 1999-10-18 Procter & Gamble Company, The Serine protease variants having amino acid substitutions
US6838269B1 (en) * 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6461849B1 (en) * 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
NZ511291A (en) * 1998-10-30 2003-08-29 Novozymes As A method for selecting a protein variant that has reduced immunogenicity as compared with the parent or wild-type protein
ATE352559T1 (de) * 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
CA2379729A1 (en) 1999-07-22 2001-02-01 The Procter & Gamble Company Protease conjugates having sterically protected clip sites
CN1369008A (zh) * 1999-07-22 2002-09-11 宝洁公司 免疫原性降低的分子内交联的枯草杆菌蛋白酶
CZ2002211A3 (cs) * 1999-07-22 2002-05-15 The Procter & Gamble Company Proteázové konjugáty se stericky chráněnými oblastmi epitopu
BR0012660A (pt) * 1999-07-22 2002-04-09 Procter & Gamble Variante de protease tipo subtilisina; composição de limpeza; e composição de cuidado pessoal
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
BR0012693A (pt) * 1999-07-22 2002-04-09 Procter & Gamble Variante, de protease tipo subtilisina; composição de limpeza; e composição de cuidado pessoal
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
WO2001083761A1 (en) * 2000-04-28 2001-11-08 Novozymes A/S Laccase mutants
RU2272644C2 (ru) 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
EP1307547B1 (de) 2000-07-28 2005-10-26 Henkel Kommanditgesellschaft auf Aktien Neues amylolytisches enzym aus bacillus sp. a 7-7 (dsm 12368) sowie wasch- und reinigungsmittel mit diesem neuen amylolytischen enzym
JP5126761B2 (ja) * 2000-10-02 2013-01-23 ジェネンコー・インターナショナル・インク 変化した免疫反応をもたらすタンパク質及びその作成または使用方法
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
CA2441595C (en) * 2001-03-23 2012-07-03 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US6969517B2 (en) 2001-05-03 2005-11-29 Emd Lexigen Research Center Corp. Recombinant tumor specific antibody and use thereof
KR20040039323A (ko) * 2001-09-04 2004-05-10 메르크 파텐트 게엠베하 개질된 인간 성장 호르몬
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
WO2003057246A1 (en) * 2001-12-31 2003-07-17 Genencor International, Inc. Proteases producing an altered immunological response and methods of making and using the same
US7332320B2 (en) 2001-12-31 2008-02-19 Genencor International, Inc. Protease producing an altered immunogenic response and methods of making and using the same
CN101177675B (zh) 2002-02-08 2014-05-21 诺维信公司 肌醇六磷酸酶变体
CA2486112A1 (en) * 2002-05-16 2003-11-27 Alk Abello A/S Allergen mutants
CN1684657A (zh) 2002-07-30 2005-10-19 金克克国际有限公司 气溶胶产生减少的配剂
US20040121953A1 (en) * 2002-08-09 2004-06-24 Chirino Arthur J. Thrombopoiesis-stimulating proteins having reduced immunogenicity
DE60335640D1 (de) 2002-10-01 2011-02-17 Novozymes As Polypeptide der gh-61-familie
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
EP2500423B1 (en) 2003-02-26 2015-06-17 Danisco US Inc. Amylases producing an altered immunogenic response and methods of making and using the same
JP2006513709A (ja) 2003-02-26 2006-04-27 ジェネンコー・インターナショナル・インク 修飾されたアミラーゼ免疫反応を示すアミラーゼ変異体、及び、これらの製造方法並びに用途
DK1639106T3 (da) 2003-06-19 2010-09-27 Novozymes As Proteaser
WO2004111224A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Improved proteases and methods for producing them
EP2284259A3 (en) 2003-10-10 2011-06-15 Novozymes A/S Protease variants
PL1673398T3 (pl) 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
RU2369616C2 (ru) 2003-12-30 2009-10-10 Мерк Патент Гмбх Слитые белки il-7
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
WO2005066339A2 (en) 2004-01-06 2005-07-21 Novozymes A/S Polypeptides of alicyclobacillus sp.
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
EP1735433B1 (en) 2004-04-02 2010-12-08 Novozymes A/S Subtilase variants having altered immunogenicity
ATE541034T1 (de) 2004-06-21 2012-01-15 Novozymes As Nocardiopsis-proteasen
AR050895A1 (es) 2004-10-04 2006-11-29 Novozymes As Polipeptidos que tienen actividad de fitasa y polinucleotidos que los codifican
BRPI0517539A (pt) 2004-10-04 2008-10-14 Novozymes As polipeptìdeo isolado, polinucleotìdeo isolado, construto de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir o polipeptìdeo, e para melhorar o valor nutricional de uma ração animal, célula de planta, parte de planta ou planta transgênica, animal não-humano, transgênico, ou produtos, ou elementos do mesmo, uso de pelo menos um polipeptìdeo, aditivo de ração animal, e, composição de ração animal
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
DE602006020923D1 (de) 2005-08-16 2011-05-05 Novozymes As Polypeptide von Stammbakterien SP P203
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
EP1960517A2 (en) 2005-12-06 2008-08-27 Genencor International, Inc. Perhydrolase epitopes
CA2633766C (en) 2005-12-21 2016-06-28 Micromet Ag Pharmaceutical compositions comprising a bispecific single chain antibody with specificity for human cd3 and human cea and having resistance to soluble cea
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
CA2635618C (en) 2005-12-30 2015-10-06 Merck Patent Gesellschaft Mit Beschraekter Haftung Interleukin-12p40 variants with improved stability
WO2007107573A1 (en) 2006-03-22 2007-09-27 Novozymes A/S Use of polypeptides having antimicrobial activity
MX2008012632A (es) 2006-04-04 2008-10-13 Novozymes As Variantes de fitasa.
WO2008079685A2 (en) 2006-12-21 2008-07-03 Novozymes A/S Lipase variants for pharmaceutical use
US8221743B2 (en) 2006-12-22 2012-07-17 Novozymes A/S Use of polypeptides against diseases caused by protozoans
US7923232B2 (en) 2007-03-26 2011-04-12 Novozymes A/S Hafnia phytase
DK2650364T3 (en) 2008-09-26 2015-06-08 Novozymes As Hafniaphytase variants
JP5781501B2 (ja) 2009-04-22 2015-09-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 改変されたＦｃＲｎ結合部位を有する抗体融合タンパク質
US8932588B2 (en) 2009-11-05 2015-01-13 Teva Pharmaceuticals Australia Pty. Ltd. Treatment of cancer involving mutated KRAS or BRAF genes
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
US20170269092A1 (en) 2014-12-02 2017-09-21 Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
CA3189083A1 (en) 2020-08-13 2022-02-17 Novozymes A/S Phytase variants and polynucleotides encoding same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903068A (en) * 1972-12-26 1975-09-02 Us Health Education & Welfare Facile synthesis of human insulin by modification of porcine insulin
DK6488D0 (da) * 1988-01-07 1988-01-07 Novo Industri As Enzymer
DK316989D0 (da) * 1989-06-26 1989-06-26 Novo Nordisk As Enzymer

Also Published As

Publication number Publication date
JP2003174871A (ja) 2003-06-24
JP2002101880A (ja) 2002-04-09
JP3355186B2 (ja) 2002-12-09
KR100237968B1 (ko) 2000-01-15
CA2095852A1 (en) 1992-06-06
DE69130113D1 (de) 1998-10-08
WO1992010755A1 (en) 1992-06-25
BR9107206A (pt) 1993-11-03
ATE170630T1 (de) 1998-09-15
JPH06502994A (ja) 1994-04-07
CA2331936C (en) 2007-07-31
EP0561907B1 (en) 1998-09-02
DK0561907T3 (da) 1999-05-31
FI932561A7 (fi) 1993-06-04
FI932561L (fi) 1993-06-04
CA2331936A1 (en) 1992-06-06
KR930703610A (ko) 1993-11-30
CA2095852C (en) 2001-05-08
EP0561907A1 (en) 1993-09-29
DE69130113T2 (de) 1999-05-12
JP3450840B2 (ja) 2003-09-29
AU9052891A (en) 1992-07-08

Similar Documents

Publication Publication Date Title
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
FI941199A0 (fi) Immunoreaktiiviset hepatiitti-C-viruksen polypeptidikoostumukset
DE69021002D1 (de) Schimärische Hepadnavirus-Kernantigenproteine.
ATE68826T1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
FI972945A0 (fi) Antigeenien antamiseen soveltuvia koostumuksia
PT97159A (pt) Processo para a preparacao de uma proteina do antigenio de superficie da hepatite b ou de um seu fragmento e processo para a preparacao de uma vacina
BR9500732A (pt) Peptídio imunologicamente ativo,fragmento de DNA isolado,kit de teste e aplicação
PT86600A (pt) Process for the preparation of anticoagulant peptides
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
DE69127401D1 (de) Durch Glas zusammengefügter Körper
CA2178635A1 (en) Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
FI892222A0 (fi) Peptidalkoholer med antikoagulantverkan.
NO900758L (no) Fremgangsmaate for fremstilling av hybridprotein.
DK0471718T3 (da) Paracetamolholdigt farmaceutisk præparat
FR2624854B1 (fr) Nouveaux sulfonamides du benzylidene camphre derivant d'aminoacides et leur application en cosmetique, notamment en tant que filtres solaires
DE69132200D1 (de) Immunaktive Peptidzusammensetzung gegen HTLV-Antikörper
DK13087A (da) Gensekvens til fremstilling af human serumalbumin i bacillus
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
NO881942D0 (no) Fremgangsmaate for fremstilling av fremmede proteiner i streptomyceten.
FI913475A0 (fi) Klass ii protein med immunologiska baerar- och foerstaerkningsegenskaper fraon yttermembranen i neisseria meningitidis och vaccin innehaollande detta.
DE68922896D1 (de) RHOPTRY-MEMBRAN-ANTIGEN VON -i(PLASMODIUM FALCIPARUM).
ATE175357T1 (de) Empfängnisverhütender impfstoff
ITFI920071A0 (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vogeesndk
NO881779D0 (no) Fremstilling av l-fenylalanin med hjelp av rekombinante bakterier.

Legal Events

Date Code Title Description
FC Application refused
FCK Appeal rejected

Free format text: APPLICATION REJECTED